von Knebel Doeberitz M, Koch M, Weitz J, Herfarth C
Sektion für Molekulare Diagnostik und Therapie, Chirurgische Universitätsklinik, Heidelberg.
Zentralbl Chir. 2000;125 Suppl 1:15-9.
Progression of malignant tumours to metastatic disease after surgery in curative intent is due to usually few and with conventional diagnostic techniques undetectable residual malignant cells. These cells must have been spread either before or during surgery. The more sensitive and specific detection of these malignant cells in various clinically relevant compartments of the patients organism became possible through new immunocytochemical and molecular tools. Various clinical studies underline the strong prognostic impact of the detection of disseminated cancer cells. However, many technical aspects did not yet allow sufficient standardization of these procedures and led to significantly varying results among different scientific groups. It is one of our primary aims to test, whether the detection of disseminated cancer cells might guide the indication for adjuvant therapies and might predict the efficacy of therapies in patients with solid cancers.
根治性手术后恶性肿瘤进展为转移性疾病通常是由于残留的恶性细胞数量很少，用传统诊断技术无法检测到。这些细胞必定是在手术前或手术期间就已扩散。通过新的免疫细胞化学和分子工具，可以更灵敏、更特异的检测患者机体各个临床相关部位的这些恶性细胞。各种临床研究都强调了检测播散癌细胞具有很强的预后影响。然而，许多技术方面的问题尚未使这些检测程序充分标准化，导致不同科研团队得到的结果差异很大。我们的主要目标之一是测试，检测播散癌细胞是否可指导辅助治疗的适应症，并能否预测实体癌患者的治疗效果。
